Dr. Raj Singh, MD is the founder, owner, and CEO of HEALOR®. He is a double board-
certified physician in Internal Medicine and Nephrology, with extensive expertise in both
comprehensive primary care and advanced kidney health management.
Dr. Singh earned his M.B.B.S From VMKV College in India, Internal Medicine residency from the UNLV School of Medicine and completed Nephrology training at the University of Kansas Medical Center.
In addition to his clinical practice, he serves as a faculty member and medical educator, contributing to the development of future healthcare professionals.
His approach to medicine blends evidence-based clinical care with a holistic, wellness-
focused philosophy. Dr. Singh emphasises prevention, longevity, and personalised
treatment plans that address the root cause of health concerns rather than only managing
symptoms.
He is widely recognised for his work in anti-aging medicine, metabolic health, hormone
optimisation (including bioidentical and gender-affirming hormone therapy), medical weight
loss, sexual health, and regenerative wellness.
Beyond patient care, Dr. Singh is a nationally recognised speaker and researcher. He has
served as a principal investigator in multinational clinical trials and regularly presents at
medical conferences across the United States and internationally.
(Clinical research experience listed below is for the past five years and includes protocol titles with XXXXX replacing names of clinical compounds.)
Dr. Singh has served as a Principal Investigator in more than 30 multinational clinical trials. (Moderna, Merck, Abbott etc)
1. 2023 A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXXX in Adults 18 to 49 Years of Age
2. 2023 A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXXX in Pneumococcal Vaccine-naïve Adults.
3. 2023 RSV Outcomes Study Extension (ROSE)
4. 2023 A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age
5. 2023 A Phase 1/2, randomized, open-label study to evaluate the safety, reactogenicity, and immunogenicity of XXXXX, XXXXX, and XXXXX candidate seasonal influenza vaccines in healthy adults 50 to 75 years of age
6. 2023 A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of XXXXX Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older
7. 2023 A Randomized, Multi-regional, Double-blind, Double-dummy Parallel group,
Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of XXXXX in Gout Patients with Hyperuricemia
8. 2023 A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment with XXXXX in Gout Patients with Hyperuricemia
9. 2023 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of XXXXX, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage3b/4) Chronic Kidney Disease
10. 2023 Roche Cancer Screening Collection Study – Lighthouse
11. 2023 Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of XXXXX in Patients with Symptomatic Heart Failure with Reduced Ejection Fraction and Receiving Spironolactone (XXXXX).
12. 2023 A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of XXXXX plus empagliflozin compared with either XXXXX or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
13. 2023 Clinical Evaluation of the XXXXX COVID-19 Ag / Flu A & B Combo Card
14. 2023 A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age)
15. 2023 Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A, or Influenza B
16. 2022 A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of XXXXX for the Prevention of Illness Due to Influenza A
17. 2022 Phase 3, randomized, observer-blind, active-comparator, controlled study to evaluate the safety and efficacy of XXXXX candidate seasonal influenza vaccine in adults 50 years and older
18. 2022 A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXXX in Pneumococcal Vaccine-naïve Adults
19. 2022 A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment with XXXXX in Gout Patients with Hyperuricemia
20. 2022 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of XXXXX, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage 3b/4) Chronic Kidney Disease
21. 2022 A parallel-group treatment, Phase 4, double-blind, three-arm study to assess efficacy and safety of XXXXX plus XXXXX compared with either XXXXX or XXXXX in participants with chronic kidney disease and type 2 diabetes
22. 2022 A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age)
23. 2021 A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of XXXXX, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age
24. 2021 Acute Respiratory Infections Global Outpatient Study (ARGOS). Janssen wants to evaluate the association between lower respiratory tract disease (LRTD) and ARI-related hospitalization in patients positive for RSV. A subset of patients positive for influenza virus or severe acute respiratory syndrome coronavirus-2 (SARSCoV2) will also be enrolled, to allow for a comparative assessment of disease burden between the 3 viral respiratory pathogens.
25. 2021 Nasal Swab Collection in Patients Symptomatic of or Confirmed Positive for COVID-19, Influenza A, or Influenza B
26. 2020 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of XXXXX in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
27. 2012 Strategies using XXXXX to avoid transfusions in chronic kidney disease.
National Talks on topics (CME approved)
– Medical weight loss therapies
– IV nutrition
– Hormone therapies and disorders
– Thyroid disorders
– Sexual dysfunction
– Hormone pellets
– Neurotoxins
– Dermal Fillers
– Nutrition and supplementation
– Bio-identical hormone therapies
– Anti-aging therapies
Outside the clinic, Dr. Singh lives an active, adventure-filled life. He enjoys spending time with his kids and pets, staying committed to fitness through regular gym training, and exploring the world through skydiving and scuba diving. These experiences reflect his belief in balance, vitality, and living fully—values he brings into his approach to patient care.
